SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQ is trending as market sentiment whipsawed sharply following former President Trump's remarks suggesting the war with Iran is "very complete," which bulls embraced as a signal to buy the dip, while many in the community remain skeptical, calling it a 'fake pump' and blatant market manipulation.

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

SPY is trending following reports that President Trump declared the conflict with Iran "very complete" and "ahead of schedule," triggering a significant market rally and a sharp reversal in oil prices from recent highs. The community is intensely debating whether these comments are genuine peace signals or a strategic market manipulation, leaving many skeptical about the true resolution of the conflict and the market's future direction.

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

Zevra Therapeutics is trending after reporting strong quarterly results driven by significant MIPLYFFA revenue, which exceeded expectations and signals a commercial breakthrough, fueling community discussions around future profitability, anticipated European approval, and the impact of a new CFO hire.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo Inc. is trending as investors weigh its upcoming earnings and potential nuclear awards against a backdrop of increasing demand for AI data center power. This creates a split in community sentiment between long-term bullishness for its advanced nuclear technology and skepticism over its pre-revenue status.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

The United States Oil Fund (USO) is highly volatile amid escalating Middle East tensions threatening global oil supply, while conflicting statements from former President Trump suggesting the conflict is "very complete" are causing sharp, contentious reversals. The market remains deeply divided on whether sustained geopolitical risks will outweigh potential de-escalation and strategic reserve releases.

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

TMC is trending as the National Oceanic and Atmospheric Administration deemed its consolidated deep-seabed mining application in substantial compliance, a critical regulatory step forward. The community views this as a major de-risking event, underscoring the strategic need for critical minerals for national security and the EV/AI revolution, with many anticipating significant future milestones.

Volatility Shares Trust - 2x Long VIX Futures ETF

Volatility Shares 2x Long VIX Futures ETF

UVIX is trending as escalating geopolitical tensions, particularly concerning a potential conflict involving Iran and its impact on rising oil prices, are driving widespread market fear and discussions of increased volatility. The community is actively debating whether to accumulate UVIX as a hedge against a market correction or if these events are already priced into the market amid perceived manipulation.

Terrestrial Energy, Inc. is an advanced nuclear technology company focused on next-generation nuclear energy systems. The company is developing the Integral Molten Salt Reactor (IMSR), an innovative type of Generation IV molten salt reactor designed to produce reliable, low-carbon heat and electricity at competitive costs. The company is headquartered in Charlotte, NC.

Terrestrial Energy Inc.

Terrestrial Energy (IMSR) is gaining attention following a new DOE agreement for its IMSR Fuel Salt production pilot and recent positive analyst coverage with a $15 price target. The community actively discusses its Integral Molten Salt Reactor technology as a "dark horse" in the advanced nuclear sector, comparing its potential to peers like OKLO, especially given its strategic position to meet escalating AI data center energy demands.

AN2 Therapeutics, Inc. operates as a global health biopharmaceutical company. The firm focuses on modern biomedical and drug development to provide transformational medicines for patients suffering from infectious diseases. The company was founded by Eric Easom, George Harrison Talbot, Joseph S. Zakrzewski and Michael R.K. Alley and is headquartered in Menlo Park, CA.

AN2 Therapeutics Inc

AN2 Therapeutics is seeing an explosive rally and volume spike, driven by a recently announced $40 million private placement. This has ignited speculation of a short squeeze among bulls, though bears are quick to point out the offering's significantly lower per-share price, raising concerns about dilution and sustainability.

Aureus Greenway Holdings, Inc. engages in the ownership and operation of public golf country clubs, namely Kissimmee Bay Country Club and Remington Golf Club. It operates through the following segments: Golf Recreation, Retail Golf Products, and Equipment and Facilities Rental, Membership Dues, Food and Beverage Services, and Ancillary Services and Amenities. The Golf Recreation, Retail Golf Products, and Equipment and Facilities Rental segment is involved in the collection of fees for every round of eighteen holes, provision of driving ranges for practice, sale of golf apparel and equipment, and rental of golf products and cars. The Membership Dues segment refers to the membership fees for customers to access the club's facilities and services for a set period or daily at the point of sale. The Food and Beverage Services segment provides culinary services such as catering. The Ancillary Services and Amenities segment offers leisure activities hosted in an on-premises clubhouse, kitchen, bar, and dining area. The company was founded on December 22, 2023 and is headquartered in Kissimmee, FL.

Aureus Greenway Holdings Inc.

AGH is gaining significant attention following its announced merger with Powerus, a drone company backed by Eric Trump and Donald Trump Jr., marking a strategic shift into the defense drone sector. The community is debating the stock's potential for government contracts and a short squeeze, contrasting with concerns around past dilution and its previous business valuation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$RGRX  I think this article will kinda &quot;tie together the future pathways for orphan drugs&quot; for investors: 
https://www.knobbe.com/blog/rare-disease-therapies-gain-momentum-with-regulatory-support-and-continued-market-growth/ 
NOTEABLE QUOTES: 
&quot;the orphan drug market is currently valued at about $216 billion USD.[xv] The market is expected to continue to grow at a compound annual growth rate (CAGR) of between about 10-12%, reaching valuation in excess of $500 billion by 2032.&quot; 
 
While it remains to be seen how the FDA will streamline the process for regulatory approval, the promised conditional approvals combined with expanded post-market surveillance may soon redefine how novel rare-disease therapies reach patients. 
 
THINK: 
Conditional approvals 
Phase IV studies afterwards 
 
This situation would UNLOCK: 
TB4 NK (orphan) EYE wouldn&#39;t it??? 
 
But think abit folks... 
Same situation would apply to: 
 
RGN-137 for EB or Epidermolysis Bullosa (orphan) skin 
-which has been patented: 
https://patents.google.com/patent/US11179443B2/en?assignee=hlb+therapeutics&amp;oq=hlb+therapeutics  
clinical trials setup and couldn&#39;t recruit: 
 
-did JJ allude to this in his latest letter???

PilotDG

Fritz Hottinger

The landscape for rare disease treatments appears to be evolving rapidly, thanks to a confluence of regulatory momentum and a booming market forecast. Statements from key federal figures in recent...

Knobbe Martens

Rare Disease Therapies Gain Momentum With Regulatory Support and Continued Market Growth | Knobbe Martens

The present invention relates to a stabilized external preparation comprising thymosin beta 4 (Tβ4) as an active ingredient. More specifically, the present invention relates to a therapeutically effective external preparation with improved stability and biological activity of Tβ4.

Google

US11179443B2 - Stabilized external preparation comprising thymosin beta 4 as an active ingredient - Google Patents

StockTwits Web

Regenerx Biopharmaceuticals

  I think this article will kinda "tie together the future pathways for orphan drugs" for investors: 


 
NOTEABLE QUOTES: 
"the orphan drug market is currently valued at about $216 billion USD.[xv] The market is expected to continue to grow at a compound annual growth rate (CAGR) of between about 10-12%, reaching valuation in excess of $500 billion by 2032." 
 
While it remains to be seen how the FDA will streamline the process for regulatory approval, the promised conditional approvals combined with expanded post-market surveillance may soon redefine how novel rare-disease therapies reach patients. 
 
THINK: 
Conditional approvals 
Phase IV studies afterwards 
 
This situation would UNLOCK: 
TB4 NK (orphan) EYE wouldn't it??? 
 
But think abit folks... 
Same situation would apply to: 
 
RGN-137 for EB or Epidermolysis Bullosa (orphan) skin 
-which has been patented: 


  
clinical trials setup and couldn't recruit: 
 
-did JJ allude to this in his latest letter???

Netlist Inc

ed james

Epidermolysis Bullosa (orphan) skin info: 
Quotes: 
&quot;The US market for epidermolysis bullosa (EB) treatments was estimated at approximately $1.3 billion in 2022 and is projected to grow significantly, with forecasts reaching $3.9 billion to $9.9 billion by 2032 and 2034. This growth is driven by factors like increasing awareness, advanced treatment options, and the substantial unmet need for EB patients. &quot; 
 
TREATMENT EXAMPLE: 
The estimated annual cost of Vyjuvek, a topical gene therapy for dystrophic epidermolysis bullosa (DEB), is approximately $630,500 per patient. This cost is based on a wholesale acquisition cost of $24,250 per vial and the assumption that a certain amount of vials will be needed for treatment, according to Anton Health. Krystal Biotech, the manufacturer, has also implemented a price cap of $900,000 annually per patient to account for potential variations in treatment needs, according to Lyfegen.  
 
THE DONKER

Epidermolysis Bullosa (orphan) skin info: 
Quotes: 
"The US market for epidermolysis bullosa (EB) treatments was estimated at approximately $1.3 billion in 2022 and is projected to grow significantly, with forecasts reaching $3.9 billion to $9.9 billion by 2032 and 2034. This growth is driven by factors like increasing awareness, advanced treatment options, and the substantial unmet need for EB patients. " 
 
TREATMENT EXAMPLE: 
The estimated annual cost of Vyjuvek, a topical gene therapy for dystrophic epidermolysis bullosa (DEB), is approximately $630,500 per patient. This cost is based on a wholesale acquisition cost of $24,250 per vial and the assumption that a certain amount of vials will be needed for treatment, according to Anton Health. Krystal Biotech, the manufacturer, has also implemented a price cap of $900,000 annually per patient to account for potential variations in treatment needs, according to Lyfegen.  
 
THE DONKER